References
1. https://www.worldometers.info/coronavirus/., August 17, 2021
2. Tabarsi, P., S. Barati, H. Jamaati, S. Haseli, M. Marjani, A. Moniri,
et al., Evaluating the effects of intravenous immunoglobulin
(IVIg) on the management of severe COVID-19 cases: a randomized
controlled trial. International immunopharmacology, 2021. 90 :
p. 107205.
3. Mohtadi, N., A. Ghaysouri, S. Shirazi, E. Shafiee, E. Bastani, T.
Kokhazadeh, et al., Recovery of severely ill COVID-19 patients by
intravenous immunoglobulin (IVIG) treatment: A case series. Virology,
2020. 548 : p. 1-5.
4. Kaveri, S., M. Maddur, P. Hegde, S. Lacroix‐Desmazes, and J. Bayry,Intravenous immunoglobulins in immunodeficiencies: more than mere
replacement therapy. Clinical & Experimental Immunology, 2011.164 : p. 2-5.
5. Ferrara, G., A. Zumla, and M. Maeurer, Intravenous
immunoglobulin (IVIg) for refractory and difficult-to-treat infections.The American journal of medicine, 2012. 125 (10): p. 1036.
e1-1036. e8.
6. Liu, X., W. Cao, and T. Li, High-dose intravenous
immunoglobulins in the treatment of severe acute viral pneumonia: the
known mechanisms and clinical effects. Frontiers in immunology, 2020.11 : p. 1660.
7. Kanjilal, S. and M.J. Mina, Passive immunity for the treatment
of influenza: quality not quantity. The Lancet Respiratory Medicine,
2019. 7 (11): p. 922-923.
8. Nimmerjahn, F. and J.V. Ravetch, Anti-inflammatory actions of
intravenous immunoglobulin. Annu. Rev. Immunol., 2008. 26 : p.
513-533.
9. Xie, Y., S. Cao, H. Dong, Q. Li, E. Chen, W. Zhang, et al.,Effect of regular intravenous immunoglobulin therapy on prognosis
of severe pneumonia in patients with COVID-19. The Journal of
infection, 2020. 81 (2): p. 318.
10. Liu, J., Y. Chen, R. Li, Z. Wu, Q. Xu, Z. Li, et al.,Intravenous immunoglobulin treatment for patients with severe
COVID-19: a retrospective multi-center study. Clinical Microbiology and
Infection, 2021.
11. Shao, Z., Y. Feng, L. Zhong, Q. Xie, M. Lei, Z. Liu, et al.,Clinical efficacy of intravenous immunoglobulin therapy in
critical ill patients with COVID‐19: a multicenter retrospective cohort
study. Clinical & translational immunology, 2020. 9 (10): p.
e1192.
12. Farrokhpour, M., N. Rezaie, N. Moradi, F.G. Rad, S. Izadi, M. Azimi,
et al., Infliximab and intravenous Gammaglobulin in hospitalized
severe COVID-19 patients in intensive care unit. Archives of Iranian
medicine, 2021. 24 (2): p. 139-143.
13. Gharebaghi, N., R. Nejadrahim, S.J. Mousavi, S.-R. Sadat-Ebrahimi,
and R. Hajizadeh, The use of intravenous immunoglobulin gamma for
the treatment of severe coronavirus disease 2019: a randomized
placebo-controlled double-blind clinical trial. BMC infectious
diseases, 2020. 20 (1): p. 1-8.
14. Herth, F.J., G. Sakoulas, and F. Haddad, Use of intravenous
immunoglobulin (Prevagen or Octagam) for the treatment of COVID-19:
retrospective case series. Respiration, 2020. 99 (12): p.
1145-1153.
15. Pourahmad, R., B. Moazzami, and N. Rezaei, Efficacy of
plasmapheresis and immunoglobulin replacement therapy (IVIG) on patients
with COVID-19. SN Comprehensive Clinical Medicine, 2020: p. 1-5.